Trial Profile
Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2020
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Central retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- 23 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 28 Oct 2014 New trial record